<DOC>
	<DOCNO>NCT01795768</DOCNO>
	<brief_summary>To assess activity FGFR inhibitor AZD4547 patient FGFR1 FGFR2 amplify breast , squamous lung stomach cancer whose cancer progress follow previous chemotherapy</brief_summary>
	<brief_title>Proof-of-Concept Study AZD4547 Patients With FGFR1 FGFR2 Amplified Tumours</brief_title>
	<detailed_description>Primary endpoint - To assess anti-tumour activity change tumour size 8 week correlation change tumour ERK1/2 phosphorylation day 10-14 . Secondary endpoint - Objective response rate AZD4547 patient tumour group - Safety tolerability AZD4547 patient - Disease control rate 8 week - Progression free survival patient tumour group</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<criteria>Inclusion criterion Female male age 25 year old . Mandatory provision archival fresh tumour biopsy confirmation FGFR gene amplification . World Health Organisation performance status 02 , minimum life expectancy 12 week propose first dose date Patient ability comply collection tumor biopsy mandatory baseline day 1014 Calcium phosphate within normal limit . At least one lesion , previously irradiate , accurately measure baseline &gt; =10 mm long diameter except lymph node must short axis &gt; =15 mm . Local disease confine stomach oesophagus consider measurable ( patient locally advanced gastrooesophageal adenocarcinoma must least one measurable nodal lesion &gt; =15mm short axis ) . Tumour specific inclusion criterion Advanced gastrooesophageal adenocarcinoma Histologically proven metastatic locally advanced inoperable adenocarcinoma stomach , low oesophagus oesophagogastric junction . Documented progression 1 2 prior course chemotherapy advanced disease , FGFR2 amplification Advanced breast carcinoma Histologically confirm metastatic locally advanced breast cancer , negative HER2 determine local laboratory . Patients locally advanced disease must recurrent , progressive , disease suitable treatment curative intent Patients ER positive disease must treat least one line hormonal therapy recurrent/progressive disease hormonal therapy time recurrence/progression Documented progression least one three prior course chemotherapy advanced disease . FGFR1 amplification Advanced squamous cell lung cancer Histologically confirm metastatic locally advanced squamous cell carcinoma lung Documented progression 1 2 prior course chemotherapy advanced disease FGFR1 amplification Exclusion criterion Treatment potent inhibitor inducer CYP3A4 , 2C8 2D6 substrate CYP3A4 within specify duration prior first dose study treatment Major surgery ( exclude placement vascular access ) within 4 week first dose study treatment Radiotherapy wide field radiation within 4 week radiotherapy limited field radiation palliation within 2 week first dose study treatment Prior exposure AZD4547 drug FGFR inhibition primary mode action Untreated brain metastasis Inadequate bone marrow reserve organ function Corrected total calcium &gt; ULN Total phosphate &gt; ULN Mean rest correct QT interval &gt; 470 msec obtain 3 consecutive electrocardiogram ( ECGs ) Any follow ophthalmological criterion : 1 ) Current evidence previous history retinal pigmented epithelium detachment ( RPED ) . 2 ) Previous laser treatment intraocular injection treatment macular degeneration . 3 ) Current evidence previous history dry wet agerelated macular degeneration . 4 ) Current evidence previous history retinal vein occlusion ( RVO ) . 5 ) Current evidence previous history retinal degenerative disease ( e.g . hereditary ) . 6 ) Current evidence previous history clinically relevant chorioretinal defect</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Non randomise</keyword>
	<keyword>Open label</keyword>
	<keyword>Multicentre</keyword>
	<keyword>Phase II biomarker study</keyword>
</DOC>